UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
BIOTECHNOLOGY

Vertex Pharmaceuticals

V

Vertex Pharmaceuticals

BiotechnologyBoston, United States
Visit Website

About Vertex Pharmaceuticals

Vertex Pharmaceuticals transformed cystic fibrosis from a life-limiting condition into one manageable with daily oral therapy, establishing itself as the defining force in CF treatment worldwide. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex is listed on Nasdaq under the ticker VRTX and has grown into one of the most closely watched names in specialty pharmaceuticals.

Cystic Fibrosis Leadership

Vertex's dominance in cystic fibrosis is built on a portfolio of CFTR modulator therapies, culminating in Trikafta (known as Kaftrio in Europe), a triple-combination treatment eligible for the vast majority of CF patients aged two and above with at least one F508del mutation. The clinical and commercial success of this franchise has made Vertex the standard-bearer for precision medicine in a rare disease setting, with regulatory approvals secured across the United States, European Union, United Kingdom, and numerous other markets.

Pipeline Expansion Beyond CF

Having secured its financial foundation through CF, Vertex has invested heavily in diversifying its pipeline across pain, kidney disease, type 1 diabetes, and haematology. Its non-opioid pain programme, centred on a Nav1.8 sodium channel inhibitor, reached late-stage trials and attracted significant attention from the broader industry as a potential alternative to opioid analgesics. In haematology, Vertex partnered with CRISPR Therapeutics to develop Casgevy, the first approved CRISPR-based gene-editing therapy, indicated for sickle cell disease and transfusion-dependent beta thalassaemia. This approval marked a milestone not only for Vertex but for the entire field of gene editing.

The company maintains major research and commercial operations across the United States, United Kingdom, and Europe, with a significant presence in London following its acquisition of a Cambridge, UK research hub. Vertex employs thousands of staff globally across research, development, medical affairs, and commercial functions.

Further information is available at vrtx.com.

Similar Companies

More in Biotechnology

I

Illumina

Illumina is the company that made whole-genome sequencing a routine laboratory tool, transforming what was once a decade-long, billion-dollar undertaking into an everyday clinical and research workflow. Founded in 1998 and headquartered in San Diego, California, Illumina develops and manufactures sequencing and array-based instruments, reagents, and informatics software used by researchers, hospitals, and public health agencies in more than 160 countries. Sequencing Platforms & Instruments The company's portfolio spans a wide range of output scales, from the compact iSeq 100 designed for low-throughput clinical applications to the NovaSeq X Series, capable of sequencing multiple human genomes per run. This breadth allows Illumina to serve single-investigator labs and national genomics programmes alike. The DRAGEN Bio-IT Platform provides on-board secondary analysis, accelerating the path from raw sequence data to actionable variant calls. Clinical Genomics & Oncology Applications Illumina's technology underpins a substantial portion of global next-generation sequencing activity in oncology, inherited disease, reproductive health, and infectious disease surveillance. Its instruments and kits are widely used for companion diagnostic development, rare disease diagnosis, non-invasive prenatal testing, and cancer genomic profiling. The company has also invested in multi-cancer early detection through its Grail subsidiary, which operates the Galleri liquid biopsy test. Listed on NASDAQ under the ticker ILMN, Illumina is a large-cap life science tools company with revenues consistently in the multi-billion-dollar range. Its customer base includes academic research centres, pharmaceutical and biotechnology companies, contract research organisations, and national health services. The company has been central to landmark population genomics initiatives, including partnerships with the UK Biobank and various national sequencing programmes launched during the COVID-19 pandemic for viral surveillance. Illumina operates manufacturing sites in San Diego and Singapore, with commercial offices across North America, Europe, and Asia-Pacific. Research and development investment has remained a defining feature of its business model, with ongoing work on short-read chemistry improvements and emerging long-read sequencing capabilities. Further information is available at illumina.com.

View profile
E

Elasmogen Ltd

Founded in Aberdeen, Scotland, Elasmogen Ltd is a privately held biopharmaceutical company advancing a proprietary platform of next-generation biologics called soloMERs. These engineered single-domain antibody-based molecules are designed to combine biologic precision with the localised activity of small molecules, drawing on an ADC-inspired conjugate strategy that the company believes can deliver safer and more effective treatment than conventional biologics alone. Lead Programme: ELN28 for Hidradenitis Suppurativa Elasmogen's lead clinical candidate, ELN28, is a first-in-class dual-acting soloMER conjugate targeting Hidradenitis Suppurativa (HS), a chronic and debilitating inflammatory skin condition characterised by painful lesions, deep nodules, abscesses, skin tunnels, and scarring. HS is recognised as a major unmet need: current treatments offer only partial benefit, and the disease carries a pronounced psychosocial burden in addition to its physical impact. ELN28 combines two clinically validated agents in a single construct, aiming to address both the inflammatory drivers and tissue pathology of HS with greater precision than existing monotherapies. Platform and Pipeline Ambitions Beyond HS, Elasmogen's soloMER platform has potential application across a broader range of immune-mediated inflammatory diseases and solid-tumour oncology indications. The company's stated vision is to lead the next wave of innovation in immune-mediated disease, developing therapies that redefine clinical practice. Elasmogen operates at the intersection of biologic drug development and novel conjugate chemistry, positioning the soloMER format as a modular, adaptable tool for addressing conditions where existing biologics fall short. Further information is available at elasmogen.com.

View profile
A

argenx

argenx built its reputation on a single, unusually productive starting point: the immune systems of llamas and other camelids, which produce a class of antibodies that proved to be a powerful foundation for engineering next-generation immunology medicines. From that scientific premise, the Belgian-American company has grown into one of the most closely watched names in immunology drug development, with a commercial product, VYVGART (efgartigimod alfa), approved in multiple markets for the treatment of generalised myasthenia gravis. Founded in 2008 and headquartered in Ghent, Belgium, with significant operations in the United States and Japan, argenx is listed on Nasdaq (ARGX) and on Euronext Brussels, reflecting its transatlantic scope. The company's pipeline is centred on FcRn biology, targeting the neonatal Fc receptor to reduce disease-causing IgG antibodies in a range of serious autoimmune conditions. This mechanism underpins efgartigimod in several additional indications under investigation, as well as other early-stage programmes in the portfolio. The company operates with a focused autoimmune disease strategy rather than pursuing broad therapeutic diversification, concentrating resources on conditions where dysregulated IgG antibodies drive pathology. Target areas include neuromuscular disease, haematology, and dermatology, among others under active clinical investigation. Further information is available at argenx.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy